Adult Genetics Clinic Data Show Consistent Diagnostic Return Across Routine Care
Adult genetic medicine no longer sits at the margins of specialty practice. Across 9,867 encounters over eight years in a high-volume academic clinic, genetic testing was ordered for 52% of new patients and produced a diagnostic result in 24% of all tests. In a field often judged against pediatric benchmarks, the adult setting proved capable of delivering substantial clinical yield while serving a wide mix of indications, ages, and care models.
The data also show a service that has already moved beyond a single-physician, in-person model. Most visits were handled in person and led by a genetics-trained physician, yet genetic counselor-only visits made up 12% of all encounters. Telemedicine remained a durable part of follow-up care as well, accounting for 39% of follow-up visits from 2023 onward. In practical terms, the clinic operated as a hybrid diagnostic service, not a narrow consultative office. That matters because adult genetic evaluation often depends on repeated counseling, test interpretation, and family-history clarification over time rather than one decisive visit.
Exome Sequencing Outperformed Common Panel Testing
The sharpest signal in the cohort came from test choice. Exome sequencing yielded diagnoses in 40% of patients, while next-generation sequencing panels, the most frequently ordered test type, returned diagnoses in only 16%. The gap is too large to ignore. Panels remain common because they are familiar, easier to target, and sometimes more readily covered by payers, but they can miss diagnoses when the phenotype spans multiple organ systems or when the causative gene is not included in a narrow assay.
Exome and genome approaches interrogate a broader swath of the coding genome, which helps explain their stronger performance in adults whose presentations may be less syndromic than in childhood and may accumulate across organ systems over decades. The 40% yield is especially notable because adult genetics often deals with patients who have already undergone years of fragmented testing elsewhere. In that setting, a broad sequencing strategy can break a diagnostic stalemate that focused panels leave unresolved.
Age Reduced Yield Without Eliminating Clinical Value
Diagnostic yield declined as age increased, but it never disappeared. Even in older age strata, yield stayed above 17%, and the yield for exome and genome sequencing remained above 30% across every age group. Age clearly influences the probability of finding a pathogenic variant, yet the adult clinic did not cross a threshold where genetic evaluation became low value. Instead, the data suggest a steadier and more nuanced pattern: younger adults may carry a higher burden of detectable monogenic disease, but older adults still return clinically actionable findings often enough to justify testing when the phenotype fits.
One sentence stands out for bedside practice: advanced age did not erase the utility of genomic testing. That should matter to clinicians who hesitate to refer older adults because of assumptions about diminishing return. Age alone is a poor substitute for phenotype-based triage.
Referral Indication Drove Large Swings in Diagnostic Probability
Referral reason shaped outcomes in a major way. Some indications produced especially high rates of pathogenic findings, while others more often ended in negative or uncertain results. The article does not reduce adult genetics to a single yield number because doing so would conceal the reality of clinical selection. A patient referred for a strongly inherited neurologic syndrome does not have the same pretest probability as someone evaluated for a broad, nonspecific symptom cluster.
This is where practice-based evidence becomes useful. Adult genetics services need age-aware and indication-aware triage because not every referral should be routed through the same test menu or the same pace of evaluation. A carefully targeted referral pathway can reserve broader sequencing for patients whose phenotype makes a monogenic diagnosis more likely, while avoiding reflexive panel ordering in low-probability settings. The variability across indications also explains why counseling remains central to the specialty: the likelihood of a positive result, a negative result, or an uncertain finding is not uniform from one referral to the next.
Operational Shifts Reflected Payer Pressure and Laboratory Policy
Testing patterns did not stay static over the eight-year period. Test type and laboratory utilization shifted in parallel with payer and laboratory policy changes, indicating that administrative decisions shaped clinical practice as much as scientific preference did. In adult genetics, the choice between panel testing and broader sequencing is not purely a medical one; it is filtered through reimbursement rules, contractual lab arrangements, and evolving coverage criteria.
Those operational shifts have direct consequences at the bedside. A patient’s chance of receiving exome sequencing may depend on where they are seen, how the payer defines medical necessity, and which laboratory the health system can access at a given time. The clinic data make clear that implementation science belongs in genomic medicine. Diagnostic yield is only part of the story; access to the right test at the right time determines whether yield can be realized at all.
What the Cohort Means for Adult Genomic Care
These findings establish adult genetics as a high-yield clinical domain with durable relevance across multiple encounter types. The service model appears workable in both in-person and telemedicine settings, and genetic counselor participation remains a meaningful part of care delivery. More importantly, the diagnostic data support a more disciplined approach to adult referral pathways: use indication-specific triage, match the test to the phenotype, and do not dismiss genomic evaluation on the basis of age alone.
The strongest implication is not that every adult needs exome sequencing. It is that broad testing has a real place in adult practice and outperforms narrower panels in many settings. The clinic data also suggest that workforce planning should account for a hybrid model in which physicians, genetic counselors, and telemedicine each contribute to volume and follow-up.
A final limitation is built into the design itself: these are practice-based data from a single high-volume academic clinic, so referral patterns, payer rules, and local expertise likely shaped the observed yields. Even so, the dataset is large enough to show that adult genetic medicine is not a niche exercise. It is a diagnostic service with measurable returns, and the choice of test, indication, and operational setting all change what patients receive.